Vaccine Poliomyelitis Inactivated (IPV)

PreclinicalVaccine

Vaccine Poliomyelitis Inactivated (IPV) is one of 3 biologic programs targeting Poliomyelitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PoliomyelitisActive, not recruiting

PoliomyelitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Poliomyelitis

#DrugCompanyPhaseTrials

Nopv2

FFidec Corporation

Phase 3

2 2

Verazinc

FFakultas Kedokteran Universitas Indonesia

Preclinical

—3

Vaccine Poliomyelitis Inactivated (IPV)

CanSino Biologics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Poliomyelitis

NCT06577298

Clinical

Trials by Indication[1]

Poliomyelitis1 trial

A Phase I/II Randomized, Double-blind, Positive-controlled Dose-exploration Study to Evaluate the Safety and Immunogenicity of a Virus-like Particle (VLP) Based Vaccine Against Poliomyelitis (VLP-Polio) in Infants From 6 Weeks of Age and Toddlers 12-18 Months of Age

Active, not recruiting· CanSino Biologics Inc. logo

CanSino Biologics Inc.·Preclinical·NCT06577298·480 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vaccine Poliomyelitis Inactivated (IPV). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vaccine Poliomyelitis Inactivated (IPV) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vaccine Poliomyelitis Inactivated (IPV). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CanSino Biologics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Preclinical[1]
Company: CanSino Biologics Inc.

Vaccine Poliomyelitis Inactivated (IPV)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Poliomyelitis1 trial

References

Drug Info

Quick Facts

Related News